Concepedia

Kevin D. Shenk

KD

Statistics

Publications

12

Citations

2.6K

H-Index

11

Active since

1994

Affiliations

Carolina Veterinary Specialists(Current)

Pfizer (United States)

Kevin D. Shenk is an author at Carolina Veterinary Specialists specializing in pharmacology, proteasome inhibitors, and proteasome inhibitor therapy.

Publications per year

1994–2011

12

Publications

12

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

Deborah J. Kuhn, Qing Chen, Peter M. Voorhees et al. · Blood · 2007 · 768 citations · Full text

, , +13

Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome

Susan D. Demo, Christopher J. Kirk, Monette Aujay et al. · Cancer Research · 2007 · 675 citations · Full text

, , +13

Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events

Shirin Arastu‐Kapur, Janet L. Anderl, Marianne Kraus et al. · Clinical Cancer Research · 2011 · 409 citations

, , +15

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome

Francesco Parlati, Monette Aujay, Érika Suzuki et al. · Blood · 2009 · 323 citations

, , +11

Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047)

Han-Jie Zhou, Monette Aujay, Mark K. Bennett et al. · Journal of Medicinal Chemistry · 2009 · 272 citations · Full text

, , +12

1–5 of 12